View Author
patient myeloma bortezomib study lenalidomide thalidomide dexamethasone treatment grade therapy response phase combination trial relapse blood disease month myeloma patients factor ef ficacy /refractory progression cancer risk strati fication university result neuropathy agent /refractory myeloma response rate cycle novel group regimen cell transplantation meeting survival risk factors abstr fication cyclophosphamide transplantation richardson signi ficance outcome signi protein hospital serum ficacy leukemia cytogenetic novel agents barlogie b oncol haematol melphalan evaluable patients ppr strati prednisone neutropenia effect ficance activity pegylated liposomal doxorubicin /refractory myeloma patients toxicity marrow gammopathy thromboembolism inhibitor lenalidomide –dexamethasone richardson pg venou consensus sonneveld p phase ii study system anemia
4 Most Recent Publications
|
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
(Article)
Corthals, S.L. Kuiper, R. Johnson, D.C. Sonneveld, P. Hajek, R. Holt, B. van der Magrangeas, F. Goldschmidt, H. Morgan, G. Avet-Loiseau, H. |
2011-11-01
|
|
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
(Article)
Donk, N.W.C.J. van de Lokhorst, H.M. Goldschmidt, H. Sonneveld, P. Johnsen, H.E. Bladé, J. San-Miguel, J-F. Palumbo, A. Dimopoulos, M.A. Cavo, M. Morgan, G. Einsele, H. Kropff, M. Schey, S. Avet-Loiseau, H. Ludwig, H. |
2011-06-01
|
|
Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
(Article)
Munshi, N.C. Anderson, K.C. Jagannath, S. Hajek, R. Sezer, O. Kyle, R. Sonneveld, P. Cavo, M. Rajkumar, S.V. San-Miguel, J-F. Crowley, J. Avet-Loiseau, H. Bergsagel, P.L. Shaughnessy, J. Palumbo, A. Durie, B.G.M. Fonseca, R. Stewart, A.K. Harousseau, J-L. Dimopoulos, M.A. |
2011-05-05
|
|
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(Article)
Kyle, R. Durie, B.G.M. San Miguel, J-F. Avet-Loiseau, H. Hajek, R. Chen, W. Anderson, K.C. Ludwig, H. Sonneveld, P. Pavlovsky, S. Palumbo, A. Richardson, P.G. Rajkumar, S.V. Barlogie, B. Greipp, P. Vescio, R. Turesson, I. Westin, J. Boccadoro, M. Landgren, O. Bladé, J. Merlini, G. Kröger, N. Einsele, H. Vesole, D. Dimopoulos, M.A. |
2010-04-22
|
